Cullen Frost Bankers Inc. decreased its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 9.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 543,052 shares of the biopharmaceutical company's stock after selling 58,539 shares during the period. Cullen Frost Bankers Inc.'s holdings in Pfizer were worth $15,634,000 as of its most recent SEC filing.
Several other institutional investors have also recently bought and sold shares of the business. Gryphon Financial Partners LLC grew its stake in shares of Pfizer by 43.7% in the 4th quarter. Gryphon Financial Partners LLC now owns 26,942 shares of the biopharmaceutical company's stock worth $861,000 after acquiring an additional 8,194 shares in the last quarter. Moss Adams Wealth Advisors LLC grew its stake in shares of Pfizer by 19.2% in the 4th quarter. Moss Adams Wealth Advisors LLC now owns 13,509 shares of the biopharmaceutical company's stock worth $389,000 after acquiring an additional 2,175 shares in the last quarter. Barlow Wealth Partners Inc. bought a new stake in shares of Pfizer in the 4th quarter worth $222,000. Patrick M Sweeney & Associates Inc. bought a new stake in shares of Pfizer in the 4th quarter worth $1,206,000. Finally, Sage Investment Advisers LLC bought a new stake in shares of Pfizer in the 4th quarter worth $211,000. Institutional investors and hedge funds own 68.36% of the company's stock.
Wall Street Analyst Weigh In
PFE has been the subject of several recent analyst reports. Argus lowered shares of Pfizer from a "buy" rating to a "hold" rating in a research note on Friday, March 22nd. Cantor Fitzgerald restated an "overweight" rating and set a $45.00 price target on shares of Pfizer in a research report on Monday, April 15th. BMO Capital Markets restated an "outperform" rating and set a $36.00 price target (up previously from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Morgan Stanley increased their price target on shares of Pfizer from $28.00 to $29.00 and gave the company an "equal weight" rating in a research report on Thursday, May 2nd. Finally, Guggenheim initiated coverage on shares of Pfizer in a research report on Friday, February 23rd. They set a "buy" rating and a $36.00 price target for the company. Eleven equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $36.00.
View Our Latest Report on PFE
Pfizer Price Performance
Shares of Pfizer stock traded up $0.50 on Wednesday, reaching $28.28. The stock had a trading volume of 39,037,887 shares, compared to its average volume of 43,541,762. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $40.37. The company has a market cap of $160.11 billion, a P/E ratio of -471.17, a price-to-earnings-growth ratio of 1.17 and a beta of 0.63. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The business's 50 day moving average is $26.92 and its two-hundred day moving average is $28.12.
Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.58%. The firm had revenue of $14.88 billion for the quarter, compared to the consensus estimate of $13.87 billion. During the same period in the prior year, the firm posted $1.23 earnings per share. The company's revenue for the quarter was down 19.5% on a year-over-year basis. As a group, research analysts anticipate that Pfizer Inc. will post 2.39 EPS for the current year.
Pfizer Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be issued a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.94%. The ex-dividend date is Thursday, May 9th. Pfizer's payout ratio is -2,799.53%.
About Pfizer
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
